 |
[Alpha Biz=(Chicago) Reporter Kim Jisun] SK Bioscience announced on the 23rd that it has resumed production of SK Cell Flu, a cell culture flu vaccine developed by SK Bioscience. It has been three years since the company stopped producing flu vaccines in 2021 when it produced the COVID-19 vaccine.
SK Bioscience announced on the 23rd that 'SKYCELFLU' was shipped from 'Andong L House', a vaccine production facility in Andong, Gyeongbuk. SK Bioscience will supply about 5 million doses of flu vaccine from the end of this year to the beginning of next year.
SKYCellflu is the world's first cell culture vaccine to be certified by the World Health Organization (WHO) for pre-qualification (PQ). WHO PQ is an evaluation qualification in which the WHO evaluates the manufacturing process, quality and clinical trial results of the vaccine and certifies its safety and effectiveness.
The U.K. Joint Committee on Vaccines and Immunity (JCVI) said it first recommends cell-cultured tetravalent vaccines through flu vaccine guidelines this year and next winter.
SKYCellflu has been licensed in 10 countries, including South Korea, Malaysia, Thailand, Singapore and Mongolia, and has currently applied for additional permits in more than 10 countries.
SKYCellflu has been licensed in 10 countries, including South Korea, Malaysia, Thailand, Singapore and Mongolia, and has applied for additional permits in more than 10 countries.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
